Mr Brinsmead is a council member at Imperial College London, a former adviser to the UK Government on life sciences, has previously held senior executive roles at ICI, Zeneca and AstraZeneca, and over the last decade has been a non-executive board member and chair on a number of private and public limited company boards.

Founded by Chairman Kevin Grainger in 2014, Eos has a portfolio of 13 investee companies including, ILC Therapeutics, 3FBio, Xelect and Cumulus Oncology, investing in four key impact areas: disease prevention and treatment; energy security, climate change and pollution; food and water security, and; sustainability of industrial processes and infrastructure.

Eos sees specific opportunities with strategic investments in novel oncology technologies and treatments and CleanTech solutions, but says it “will remain active on a deal-by-deal basis in all four of the wider impact areas”.

Andrew McNeill, managing partner, Eos Advisory, said: “We have always had an enormous amount of respect for Chris’s achievements in the UK and international pharmaceutical sector, and have then had the pleasure of working more closely with Chris on Cumulus Oncology and other Eos-backed ventures in recent times. Bringing Chris on board is a milestone event for the firm and is a sign of our ambitions for the future.”

Chris Brinsmead added: “Meeting the team over the last two years and investing in a couple of their companies I realised that I was fully aligned with the goals of the Eos partners. Eos is a group of hugely talented, diverse individuals with tremendous experience. I believe that by joining the partnership, I can help to strengthen their work and potentially increase the impact.

“I am excited to identify and work with startup companies, conceived in Scotland, focussed on four distinct themes, all of which can have an impact worldwide. Some of these companies may grow to be global players, making a positive impact on the environment and human health.”